Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
about
Revolutionizing Alzheimer's disease and clinical trials through biomarkersDrug development in Alzheimer's disease: the path to 2025Memory loss in Alzheimer's diseaseNormative data for the Rappel libre/Rappel indicé à 16 items (16-item Free and Cued Recall) in the elderly Quebec-French population.Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial.The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working GroupGeneral cognitive status among Baby boomers and pre-boomers in Taiwan: the interplay between mid-life socioeconomic status and city residence.10-minute delayed recall from the modified mini-mental state test predicts Alzheimer's disease pathologyThe free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's diseaseClinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's diseaseComparison of "Word" vs. "Picture" Version of the Free and Cued Selective Reminding Test (FCSRT) in Older Adults.Oxidative Stress and Its Clinical Applications in DementiaFree and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's diseaseShort-term delayed recall of auditory verbal learning test is equivalent to long-term delayed recall for identifying amnestic mild cognitive impairment.Plasma proteomics for the identification of Alzheimer disease.Screening for predementia AD: time-dependent operating characteristics of episodic memory testsLow Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women.Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairmentOptimizing Neuropsychological Assessments for Cognitive, Behavioral, and Functional Impairment Classification: A Machine Learning StudyIdentifying memory impairment and early dementia in primary care.CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease.Two-stage screening for early dementia in primary care.A normative study of the Italian printed word version of the free and cued selective reminding test.The free and cued selective reminding test: Validation for mild cognitive impairment and Alzheimer's disease.Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.Neuropsychological predictors of conversion to probable Alzheimer disease in elderly with mild cognitive impairment.On the path to 2025: understanding the Alzheimer's disease continuum.Conventional and robust norming in identifying preclinical dementia.Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.Cued recall measure predicts the progression of gray matter atrophy in patients with amnesic mild cognitive impairment.Free and Cued Selective Reminding Test sensitivity.Recalling feature bindings differentiates Alzheimer's disease from frontotemporal dementia.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
P2860
Q26744882-6C430804-467D-4363-9DA3-9C7BF1E9BED2Q27007748-38903729-B7B4-42B1-8439-5536FA8A9145Q27687485-2846C497-390F-4BF6-BC85-3BF6319AFFFAQ30818446-264EF288-12BB-49D2-98D1-F740C4B79F01Q30996721-20133C3A-82FD-4961-86FC-F694C44B2B05Q33568361-599D2C81-5973-4F88-871B-2CF3448AF945Q33730660-F6D8CF3C-B4A8-4985-86B4-39CB8BB032C0Q34455346-DC36E782-2F4A-4A18-877D-E1CF4F457DD7Q34683582-2F33744B-7828-48F4-9D65-2BFA4178CE35Q35284971-CD1EAFAD-66C3-47CA-A10A-BAE9F154961FQ35353699-0D5DC550-42B2-4B2A-ABBF-AA567ACD4FB6Q35623258-D1819AD5-141A-4B04-AC52-1B02A9007C20Q35776386-CFD5E6BE-82CE-48F0-AFEA-82FE0A10034AQ36453758-8CA5F35E-78FF-45F9-B8BA-C1008B04F1C2Q36767124-6EF51723-14B0-45E0-A7B9-8A94DAEFBFA7Q36850876-B6EDAA85-387C-46A5-A3DD-578769EB76A0Q37136780-58BBE81B-5105-483E-81A7-85020FE0B05BQ37139940-94857CD0-E31C-40F3-9CF9-F8A7880CD4D7Q37640130-E027360C-9EDA-4F12-9EC0-4423475D4CA0Q37682700-0C51DB49-9581-474D-B279-70CA3081296EQ38012590-43A5FF20-CFE8-4C69-8CBD-C977661FE13FQ38252671-B3234F80-1DC8-4DE2-9061-53D8296888C7Q38391652-24EA61AD-75F4-417D-83A5-F0905A42BB14Q38411923-A0F9EAC0-A73B-4BE6-B664-66A031F8BD59Q38428966-5F0AE92D-A824-4AB9-82A2-237A1DE63C94Q38808542-FCB65126-3402-4BCE-96F8-987E659D9A39Q38901571-372A8DD7-85E9-4A68-924A-BD98B6F4C18BQ38933111-206EE850-82BB-43ED-918A-6EE9CA138FFAQ40410694-E6845F30-6485-4C9C-B4F2-EC8004C3F443Q40873275-5A07FB38-77EF-4184-9887-05608350465FQ41159802-E318FE42-BF4B-42E2-B7F0-5867B4C7CE9FQ41318515-4727188C-1FE8-40D8-9679-C86EAF064E8DQ41435198-7396F9F3-E865-4B69-A8B3-4D2687BB2A21Q42374123-28D58984-96AC-4401-B0D8-326F69879C25Q45193873-DD4677B5-757F-44FC-BA96-CD84CF0F9AE3Q46641382-6F63AA61-8CFF-4D71-9ECE-DF182B36D7CDQ47158579-C0E9C969-CCBB-4BB4-904C-CD720F2E070FQ47551819-2534014B-A2C5-4842-9580-D2262C59BD98Q47587631-85C72010-3062-41A6-BDD2-37F3846DAC31Q47604662-4CD4743F-ED96-498B-ACAD-122764F1BFF3
P2860
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@en
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@nl
type
label
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@en
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@nl
prefLabel
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@en
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@nl
P2093
P50
P1433
P1476
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
@en
P2093
C Luckhaus
F M Reischies
J Schröder
P304
P356
10.1212/WNL.0B013E318245F447
P407
P577
2012-01-11T00:00:00Z